Science and entrepreneurship with patients first

We are an international and diverse team of scientists, visionary innovators, and experienced business leaders, dedicated to shaping the future of targeted therapies

The SmartCella Manifesto

At SmartCella, we are driven by passion: we aim to bring cures and transform the lives of patients in need by pioneering new treatment paradigms based on world-class science.

The combination of first-in-class delivery platforms and cutting-edge development and manufacturing of cell-mediated therapies sets us apart. With the Extroducer®, we offer a novel endovascular delivery device that enables injection directly into hard-to-reach organs and tumors. We have capabilities within allogeneic cell therapy development and GMP manufacturing with a focus on heart failure and Parkinson’s disease.  And we develop novel mRNA therapies and technologies, with novel modes of delivery.

Key milestones

Humble beginnings

ProCella and SmartWise are founded

Development of cardiac cell therapy – ProCella

Research and collaboration agreement established with AstraZeneca

Formation of SmartCella Holding AB

Led by € 20M investment by Fjarde AP-Fonden

Catheter GLP study – SmartWise

Catheter GLP study demonstrates safe and effective drug delivery to abdominal organs in January, 2021

Cardiac progenitor cells POC – ProCella

Large animal POC study delivering cardiac progenitors to the heart completed in collaboration with AstraZeneca in April, 2021

Second investment round – SmartCella

€ 30M investment from AMF, SEB, Celox, and AltoCumulus in September, 2021

Candidate drug nomination – ProCella

Candidate drug nomination of cardiac progenitor cells by AstraZeneca in December, 2021

Catheter receives 510(k) clearance

The first version of the Extroducer receives 510(k) clearance by US FDA

GLP tox study completed – ProCella

GLP tox study for cardiac progenitor cells completed in collaboration with AstraZeneca in June, 2023

GMP manufacturing licensure – ProCella

GMP manufacturing authorization received from Läkemedelsverket, the Swedish Medical Products Agency in December, 2023

50 million EUR raised

Execution of 50m EUR funding with strong new shareholders AstraZeneca, Handelsbanken Fonder, & RoosGruppen

Agreement with XyloCor Therapeutics

First commercial agreement for the Extroducer signed with XyloCor Therapeutics

Delivering on the promise of targeted therapies

A culture that fosters innovation


Transparency


Creativity


Trust


Collaboration

Join our team that is shaping the future of targeted therapies

Leadership team

Meet our management team that brings together with broad experience across development, manufacturing, and commercialization disciplines

Board members

SmartCella’s goal is to become a global leader in targeted delivery of therapeutics. Here you will find materials related to our shareholders, such as Annual Reports and supporting materials for General Meetings.

Let’s pioneer the future of targeted therapies together